Board of Directors

Michael Hunkapiller, Ph.D.

Chairman, CEO & President

Michael Hunkapiller became President & CEO of Pacific Biosciences in 2012. He is Chairman of PacBio’s Board of Directors, and has served on the Board since 2005. Dr. Hunkapiller spent over 30 years of his career helping build Applied Biosystems (“ABI,” now part of Thermo Fisher Scientific Inc.) into a market leader in the life sciences industry. From 1995 to 2004, he served as ABI’s President and General Manager. In 2004, he joined Alloy Ventures as a General Partner, and in 2005 led Alloy’s investment in PacBio. Dr. Hunkapiller continues to represent Alloy Ventures as a Director of NuGEN and RainDance Technologies.

During his term at ABI, Dr. Hunkapiller developed the R&D strategies and alliances that elevated ABI to be the foremost supplier of molecular-biology reagents and instrumentation in academic and industrial laboratories. He was also a founder of ABI’s sister company, Celera Genomics, and Senior Vice President of Applera Corporation (Celera’s parent company).

Prior to joining ABI, Dr. Hunkapiller was a senior research fellow in the Division of Biology at the California Institute of Technology. He received a B.S. in Chemistry from Oklahoma Baptist University and a Ph.D. in Chemical Biology from the Division of Chemistry and Chemical Engineering at Caltech. He has authored more than 100 scientific publications, is an inventor on more than two-dozen patents, and has served on the editorial boards of several scientific journals. He has received several awards for his contributions to life science research.

David Botstein

Chief Scientific Officer, Calico Life Sciences, LLC

David Botstein, Ph.D., is Chief Scientific Officer of Calico Life Sciences, LLC. He is also Anthony B. Evnin Professor of Genomics, Emeritus at Princeton University, where he also served as Director of the Lewis-Sigler Institute for Integrative. From 1990-2003 he was Chairman of the Department of Genetics at Stanford University. From 1987-1990 he was Vice President for Science at Genentech and remained a member of its Science Resource Board until 2014. He is a member of the National Academy of Sciences and the Institute of Medicine, and has received numerous awards for his achievements in science. Dr. Botstein made fundamental contributions to modern genetics, including the discovery of many yeast and bacterial genes and the establishment of key techniques that are commonly used today. In 1980, Botstein and three colleagues proposed a method for mapping genes that laid the groundwork for the Human Genome Project. Dr. Botstein holds a Ph.D. in Human Genetics from the University of Michigan and an A.B. in Biochemical Sciences from Harvard.

Brook Byers

Partner, Kleiner Perkins Caufield & Byers (KPCB)

Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors.

He is currently on the Board of Directors of CareDX, Enjoy Technology, Octoave Bioscience, Oculeve, Pacific Biosciences, Inc. and Zephyr Health.  He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Hybritech (Chairman), Genprobe and others. These companies have pioneered the medical use of molecular biology, monoclonal antibodies, molecular diagnostics and genomics.

Brook was President and a Director of the Western Association of Venture Capitalists. Brook is currently on the Board of Trustees of Stanford University.  He also serves on teh Board of Overseers of the University of California San Francisco medical campus and hospitals and the Board of Director of the New Schools Foundation.  In 2007, UCSF awarded Brook the UCSF Meda., its honorary degree equivalent.  In 2008, he received the Lifetime Achievement Award from the National Venture Capital Association.  In 2010, he received an honorary Ph.D. from Georgia Institute of Technology.  He earned a B.S. in electrical engineering from Georgia Tech and an M.B. A. from Stanford University. 

Bill Ericson

Managing Partner, Mohr Davidow Ventures (MDV)

William Ericson has been a member of our Board of Directors since 2004 and our Lead Independent Director since 2010. Mr. Ericson is a Founding Partner at Wildcat Venture Partners where he focuses on investments in the Digital Health. He is also a General Partner at Mohr Davidow Ventures (MDV) where he has led the firm’s focus on personalized medicine investing since 2003. Bill has been working with startups for his entire career, and partners with strong minded entrepreneurs who want to attack big markets and want help that can accelerate their vision.

Mr. Ericson holds a B.S.F.S. from Georgetown University School of Foreign Service and a J.D. from Northwestern University School of Law. We believe that Mr. Ericson possesses specific attributes that qualify him to serve as a member of our Board of Directors, including his experience with multiple companies in the life sciences industry and his focus on companies with molecular diagnostic platforms that will enable the vision of personalized medicine.

Randy Livingston

Vice President for Business Affairs and Chief Financial Officer, Stanford University

Randy Livingston has been  Vice President for Business Affairs and Chief Financial Officer of Stanford University since 2001.  Before joining Stanford in 2001, Mr. Livingston spent 16 years as a finance, marketing, and corporate development executive for several Silicon Valley companies and six years as a consultant at McKinsey & Company. Mr. Livingston currently serves as a director of Genomic Health, eHealth, Inc., and the Stanford Management Company. Mr. Livingston holds a B.S. in Mechanical Engineering from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

John F. Milligan, Ph.D.

President and Chief Operating Officer, Gilead Sciences

Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.

Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008. In 2008, Dr. Milligan joined the board of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization. Dr. Milligan is a Trustee of Ohio Wesleyan University.

Dr. Milligan received his B.A. from Ohio Wesleyan University, his Ph.D. in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.

Marshall L. Mohr

Senior Vice President & Chief Financial Officer, Intuitive Surgical

Marshall L. Mohr joined Intutive Surgical in March 2006.  Prior to that, Mr. Mohr was Vice President and Chief Financial Officer of Adaptec, Inc. Prior to joining Adaptec in July 2003, Mr. Mohr was an Audit Partner with PwC where he was most recently the Managing Partner of the firm's West Region Technology Industry Group and led its Silicon Valley accounting and auditing advisory practice.

Mr. Mohr received his B.B. A. in Accounting and Finance from Western Michigan University. Mr. Mohr also serves on the board of directors of Plantronics, Inc.

Kathy Ordonez


Kathy Ordoñez brings more than 30 years of experience in the life sciences and diagnostics industries. Previously, Ms. Ordoñez was a Senior Vice President at Quest Diagnostics where she was initially responsible for leading the company’s R&D effort and later provided oversight to multiple businesses commercializing diagnostic products and testing services. She joined Quest Diagnostics as part of its acquisition of Celera Corporation in 2011. Ms. Ordoñez was previously the Chief Executive Officer at Celera and a founder of Celera Diagnostics. Under her leadership, Celera became the leading provider of genetic testing products for HIV resistance, cystic fibrosis and high complexity tissue transplantation. Earlier in her career, Ms. Ordoñez held several senior positions at Hoffmann- La Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the Polymerase Chain Reaction (PCR) technology to the research, diagnostic and forensic fields.

Lucy Shapiro

Developmental Biology Professor, Stanford University School of Medicine

Dr. Shapiro currently serves as the Virginia and D.K. Ludwig Professor of Cancer Research and the Director of the Beckman Center for Molecular and Genetic Medicine at Stanford University's School of Medicine, where she has been as a faculty member since 1989. Dr. Shapiro is a co-founder and director of Anacor Pharmaceuticals, Inc. In 1989, Dr. Shapiro founded Stanford University's Department of Developmental Biology, and served as its Chairman from 1989 to 1997. Prior to that, Dr. Shapiro served as Chair of the Department of Microbiology and Immunology in the College of Physicians and Surgeons of Columbia University. She received a B.A. from Brooklyn College and a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine.

Dr. Shapiro has received numerous awards and has been elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences for her work in the fields of molecular biology and microbiology. Dr. Shapiro previously served as a non-executive director of GlaxoSmithKline plc from 2001 to 2006.

Stock Quote

Price $5.05
Last Trade 4:00 PM ET
Apr 21, 2017
Change $+0.33
Change (%) +6.992%
Volume 1,988,089
52 Week High 10.70
52 Week Low 3.76
Day High 5.09
Day Low 4.73
Delayed at least 20 minutes.


Pacific Biosciences

1305 O’Brien Drive

Menlo Park, CA  94025